- Home
- EE vs VRCA Comparison
EE vs VRCA Comparison
Compare EE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- VRCA
- Stock Information
- Founded
- EE 2003
- VRCA 2013
- Country
- EE United States
- VRCA United States
- Employees
- EE N/A
- VRCA N/A
- Industry
- EE Oil/Gas Transmission
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- VRCA Health Care
- Exchange
- EE Nasdaq
- VRCA Nasdaq
- Market Cap
- EE 430.8M
- VRCA 363.1M
- IPO Year
- EE 2022
- VRCA 2018
- Fundamental
- Price
- EE $17.92
- VRCA $1.91
- Analyst Decision
- EE Buy
- VRCA Strong Buy
- Analyst Count
- EE 6
- VRCA 3
- Target Price
- EE $22.00
- VRCA $12.00
- AVG Volume (30 Days)
- EE 162.8K
- VRCA 1.5M
- Earning Date
- EE 08-07-2024
- VRCA 08-14-2024
- Dividend Yield
- EE 0.56%
- VRCA N/A
- EPS Growth
- EE 4.17
- VRCA N/A
- EPS
- EE 1.12
- VRCA N/A
- Revenue
- EE $898,981,000.00
- VRCA $13,908,000.00
- Revenue This Year
- EE N/A
- VRCA $369.96
- Revenue Next Year
- EE $30.00
- VRCA $185.01
- P/E Ratio
- EE $16.03
- VRCA N/A
- Revenue Growth
- EE N/A
- VRCA 61.61
- 52 Week Low
- EE $13.38
- VRCA $1.89
- 52 Week High
- EE $20.66
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- EE 37.11
- VRCA 19.69
- Support Level
- EE $17.73
- VRCA $2.11
- Resistance Level
- EE $18.58
- VRCA $2.44
- Average True Range (ATR)
- EE 0.51
- VRCA 0.27
- MACD
- EE -0.19
- VRCA 0.06
- Stochastic Oscillator
- EE 7.36
- VRCA 1.67
About EE Excelerate Energy Inc.
Excelerate Energy Inc is engaged in flexible LNG solutions, providing integrated services along the LNG value chain. The company offers a full range of flexible regasification services from FSRUs to infrastructure development, to LNG and natural gas supply.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.